Compare Novo Nordisk A/S (NVO) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while iShares 1 3 Year Treasury Bond ETF trades at $81.19 (market cap $26.68B). The key difference: Novo Nordisk A/S is far larger — about 6.2× iShares 1 3 Year Treasury Bond ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while iShares 1 3 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and iShares 1 3 Year Treasury Bond ETF for 63 Days on average.
| NVO | SHY | |
|---|---|---|
Market Cap | $165.31B | $26.68B |
Volume | 11,432,838 | 4,077,691 |
Sector | Health | Fixed Income |
52-Week High | $63.98 | $83.18 |
52-Week Low | $35.29 | $81.05 |
Typical Hold Time | 116 Days | 63 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
SHY trades at $81.20 with minimal daily movement (+0.05%), showing stability amid broader bond market volatility. Technical indicators signal a bearish trend with moving averages pointing downward, though oscillators remain neutral. Recent dividend payments of $0.24-$0.25 per share provide consistent income, but key financial ratios are unavailable for fundamental assessment. The ETF faces headwinds from rising Treasury yields and persistent inflation pressures affecting fixed income markets.
Outlook remains cautious as SHY navigates a challenging interest rate environment. The fund benefits from short-duration focus during Fed tightening cycles but faces pressure from bond market selloffs. Investment opportunity lies in yield advantage over cash, while risks include further rate hikes and prolonged inflation. Institutional sentiment appears mixed given conflicting technical signals and macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
